- 22/12/2007
- 9,061
- 5
- 98
De vez em quando surgem pesquisas assim. Entretanto, apesar de muitas vezes, no meio enteogênico, associamos os cogumelos a transformações pessoais consideráveis, lembro que o sentido usado para cura no meio médico é bem diferente.
E quem tiver algum dos distúrbios mencionados não deve pensar que vai fazer a sua própria experiência e se curar, sem ajuda profissional.
A primeira parte:
Scientific American Mind - December, 2007
Psychedelic Healing?
Hallucinogenic drugs, which blew minds in the 1960s, soon may be used to treat mental ailments
By David Jay Brown
http://www.sciam.com/media/inline/841C3B86-E7F2-99DF-3892F6AE8C3ADFEC_1.jpg
PHILIP WHEELER www.agoodson.com
Mind-Bending Therapies
The past 15 years have seen a quiet resurgence of psychedelic drug research as scientists have come to recognize the long-underappreciated potential of these drugs. In the past few years, a growing number of studies using human volunteers have begun to explore the possible therapeutic benefits of drugs such as LSD, psilocybin, DMT, MDMA, ibogaine and ketamine.
Much remains unclear about the precise neural mechanisms governing how these drugs produce their mind-bending results, but they often produce somewhat similar psychoactive effects that make them potential therapeutic tools. Though still in their preliminary stages, studies in humans suggest that the day when people can schedule a psychedelic session with their therapist to overcome a serious psychiatric problem may not be that far off.
The Trip Begins
Psychedelic drug research began in 1897, when German chemist Arthur Heffter first isolated mescaline, the primary psychoactive compound in the peyote cactus. In 1943 Swiss chemist Albert Hofmann discovered the hallucinogenic effects of LSD (lysergic acid diethylamide) at Sandoz Pharmaceuticals in Basel while studying ergot, a fungus that grows on rye. Fifteen years later, in 1958, he was the first to isolate psilocybin and psilocin—the psychoactive components of the Mexican “magic mushroom,” Psilocybe mexicana.
Before 1972, close to 700 studies with psychedelic drugs took place. The research suggested that psychedelics offered significant benefits: they helped recovering alcoholics abstain, soothed the anxieties of terminal cancer patients, and eased the symptoms of many difficult-to-treat psychiatric illnesses, such as obsessive-compulsive disorder.
For example, between 1967 and 1972 studies in terminal cancer patients by psychiatrist Stanislav Grof and his colleagues at Spring Grove State Hospital in Baltimore showed that LSD combined with psychotherapy could alleviate symptoms of depression, tension, anxiety, sleep disturbances, psychological withdrawal and even severe physical pain. Other investigators during this era found that LSD may have some interesting potential as a means to facilitate creative problem solving.
Between 1972 and 1990 there were no human studies with psychedelic drugs. Their disappearance was the result of a political backlash that followed the promotion of these drugs by the 1960s counterculture. This reaction not only made these substances illegal for personal use but also made it extremely difficult for researchers to get government approval to study them.
Things began to change in 1990, when “open-minded regulators at the FDA decided to put science before politics when it came to psychedelic and medical marijuana research,” says Rick Doblin, a public policy expert and head of the Multidisciplinary Association for Psychedelic Studies (MAPS). “FDA openness to research is really the key factor. Also, senior researchers who were influenced by psychedelics in the sixties now are speaking up before they retire and have earned credibility.” Chemist and neuropharmacologist David E. Nichols of Purdue University adds, “Baby boomers who experienced the psychedelic sixties are now mature scientists and clinicians who have retained their curiosity but only recently had the opportunity to reexplore these substances.”
Research Begins Anew
The efforts of two privately funded organizations have catalyzed much of the recent wave of research: MAPS, founded in 1986 by Doblin, and the Heffter Research Institute, started in 1993. Outside the U.S. there are groups such as the Beckley Foundation in England and the Russian Psychedelic Society. These seek out interested researchers, assist in developing the experimental design for the studies, and help to obtain funding and government approval to conduct clinical trials. They have initiated numerous FDA-approved clinical trials in the U.S., Switzerland, Israel and Spain. So far the agency has approved seven studies, with two under review and more on the way.
E quem tiver algum dos distúrbios mencionados não deve pensar que vai fazer a sua própria experiência e se curar, sem ajuda profissional.
A primeira parte:
Scientific American Mind - December, 2007
Psychedelic Healing?
Hallucinogenic drugs, which blew minds in the 1960s, soon may be used to treat mental ailments
By David Jay Brown
http://www.sciam.com/media/inline/841C3B86-E7F2-99DF-3892F6AE8C3ADFEC_1.jpg
PHILIP WHEELER www.agoodson.com
Mind-Bending Therapies
- The drugs that put the “psychedelic” into the sixties are now the subject of renewed research interest because of their therapeutic potential.
- Psychedelics such as LSD and the compound in magic mushrooms could ease a variety of difficult-to-treat mental illnesses, such as chronic depression, post-traumatic stress disorder, and drug or alcohol dependency.
- Clinical trials with various substances are now under way in humans.
The past 15 years have seen a quiet resurgence of psychedelic drug research as scientists have come to recognize the long-underappreciated potential of these drugs. In the past few years, a growing number of studies using human volunteers have begun to explore the possible therapeutic benefits of drugs such as LSD, psilocybin, DMT, MDMA, ibogaine and ketamine.
Much remains unclear about the precise neural mechanisms governing how these drugs produce their mind-bending results, but they often produce somewhat similar psychoactive effects that make them potential therapeutic tools. Though still in their preliminary stages, studies in humans suggest that the day when people can schedule a psychedelic session with their therapist to overcome a serious psychiatric problem may not be that far off.
The Trip Begins
Psychedelic drug research began in 1897, when German chemist Arthur Heffter first isolated mescaline, the primary psychoactive compound in the peyote cactus. In 1943 Swiss chemist Albert Hofmann discovered the hallucinogenic effects of LSD (lysergic acid diethylamide) at Sandoz Pharmaceuticals in Basel while studying ergot, a fungus that grows on rye. Fifteen years later, in 1958, he was the first to isolate psilocybin and psilocin—the psychoactive components of the Mexican “magic mushroom,” Psilocybe mexicana.
Before 1972, close to 700 studies with psychedelic drugs took place. The research suggested that psychedelics offered significant benefits: they helped recovering alcoholics abstain, soothed the anxieties of terminal cancer patients, and eased the symptoms of many difficult-to-treat psychiatric illnesses, such as obsessive-compulsive disorder.
For example, between 1967 and 1972 studies in terminal cancer patients by psychiatrist Stanislav Grof and his colleagues at Spring Grove State Hospital in Baltimore showed that LSD combined with psychotherapy could alleviate symptoms of depression, tension, anxiety, sleep disturbances, psychological withdrawal and even severe physical pain. Other investigators during this era found that LSD may have some interesting potential as a means to facilitate creative problem solving.
Between 1972 and 1990 there were no human studies with psychedelic drugs. Their disappearance was the result of a political backlash that followed the promotion of these drugs by the 1960s counterculture. This reaction not only made these substances illegal for personal use but also made it extremely difficult for researchers to get government approval to study them.
Things began to change in 1990, when “open-minded regulators at the FDA decided to put science before politics when it came to psychedelic and medical marijuana research,” says Rick Doblin, a public policy expert and head of the Multidisciplinary Association for Psychedelic Studies (MAPS). “FDA openness to research is really the key factor. Also, senior researchers who were influenced by psychedelics in the sixties now are speaking up before they retire and have earned credibility.” Chemist and neuropharmacologist David E. Nichols of Purdue University adds, “Baby boomers who experienced the psychedelic sixties are now mature scientists and clinicians who have retained their curiosity but only recently had the opportunity to reexplore these substances.”
Research Begins Anew
The efforts of two privately funded organizations have catalyzed much of the recent wave of research: MAPS, founded in 1986 by Doblin, and the Heffter Research Institute, started in 1993. Outside the U.S. there are groups such as the Beckley Foundation in England and the Russian Psychedelic Society. These seek out interested researchers, assist in developing the experimental design for the studies, and help to obtain funding and government approval to conduct clinical trials. They have initiated numerous FDA-approved clinical trials in the U.S., Switzerland, Israel and Spain. So far the agency has approved seven studies, with two under review and more on the way.
os:
